Company Profile

Nostrum Pharmaceuticals LLC (AKA: Nostrum Technologies Llc)
Profile last edited on: 8/31/2017      CAGE: 6XVR4      UEI:

Business Identifier: Specialty pharmaceutical products and controlled-release, orally-administered, branded and generic drugs
Year Founded
1995
First Award
2013
Latest Award
2013
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1370 Hamilton Street
Somerset, NJ 08873
   (732) 543-2440
   info@nostrumpharma.com
   www.nostrumpharma.com
Location: Single
Congr. District: 12
County: Somerset

Public Profile

Nostrum Pharmaceuticals is engaged in the formulation and commercialization of specialty pharmaceutical products and controlled-release, orally-administered, branded and generic drugs. With controlled-release drug delivery technologies incresaingly used to improve therapy, these technologies allow for the development of “patient-friendly” dosage forms, reducing the frequency of drug administration and often improving patient compliance. Controlled-release pharmaceuticals can be especially beneficial for certain patient populations, such as the elderly, who often require several medications with differing dosing regimens. Nostrum Pharmaceuticals has a rich portfolio of approved and filed Intellectual Property supported by research and development in India through its Enem Nostrum facility as well as technology transfer and production at its Nostrum Laboratories, Inc facility in Kansas City, MO.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $224,916
Project Title: IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs
2013 1 NIH $224,916
Project Title: IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs

Key People / Management

  Nirmal Mulye -- Founder; President

  Eric Mittleberg -- Chief Operating Officer

  Rohinton Toddywala -- Chief Executive Officer

  Ronnie Toddywala